Effects of Intensive Glucose Lowering in Type 2 Diabetes

09/06/2008

the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events.

These findings identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes.


On the countrary, the ADVANCE collaborative Group (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) the effects of intensive glucose control on vascular outcomes remain uncertain, but a strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy.

Collegamenti associati

• Intensive Glycemic Control in the ACCORD and ADVANCE Trials
• Effects of Intensive Glucose Lowering in Type 2 Diabetes - NEJM - ACCORD
• ClinicalTrials.gov number, NCT00000620
• Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes - NEJM - ADVANCE
• (ClinicalTrials.gov number, NCT00145925

Notizie collegate

• 19/02/2010
• 10/01/2010 HbA1c and diabetes diagnosis
• 02/12/2009 A self-assessment score helps identify undiagnosed diabetes
• 27/11/2009
• 20/02/2009 NSH: Why not report eAG?
• 29/01/2009 AACC Position on eAG